Key result
GLP-1 RAs fail to reduce composite kidney outcomes in established CKD.
Why the study?
Differences in outcome definitions, CKD severity, and limited representation of non-diabetic CKD populations have hindered clarity on the renal and cardiovascular effects of GLP-1 RAs in CKD.
Do GLP-1 receptor agonists improve composite kidney outcomes or annual eGFR slope in adults with established chronic kidney disease?
Meta-Analysis
Do GLP-1 receptor agonists improve composite kidney outcomes or annual eGFR slope in adults with established chronic kidney disease?
Hazard Ratio: 0.79 (95% CI 0.43–1.45)
p-value: p=0.125
Among adults with established CKD, available randomized trial data demonstrated a numerically favorable but non-significant effect of GLP-1 RAs on composite kidney outcomes and eGFR slope, heavily limited by a small number of independent trial populations.
No significant kidney benefit seen with GLP-1 RAs in CKD; leaves open efficacy and supports larger RCTs with standardized endpoints.
individual meta-analyses, differences in outcome definitions and CKD severity, and the limited representation of non-diabetic CKD populations.Larger randomized trials with standardized kidney outcomes and longer follow-up are needed to clarify the renal and cardiovascular effects of GLP-1 RAs across diverse CKD populations.
No takes yet. Share an insight, caveat, or question.
Eskandar et al. (2026) conducted a meta-analysis in Established chronic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) vs. Placebo, usual care, or active comparators was evaluated on Composite kidney outcome (HR 0.79, 95% CI 0.43-1.45, p=0.125). GLP-1 receptor agonists showed a numerically favorable but statistically nonsignificant association with the composite kidney outcome (HR 0.79) in adults with established chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: